Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic
Viruses · 24.01.2023 · 15 (2) · 322
DOI: 10.3390/v15020322 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Viruses, online erschienen am 24.01.2023. Verfasst von Luis Buzón und 16 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Division, Hospital Universitario de Burgos, 09006 Burgos, Spain. Hauptthemen laut MEDLINE: COVID-19, HIV Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Dolutegravir (DTG) based dual therapies for treating PLWHIV are a standard of care nowadays. Switching to DTG and lamivudine (3TC) safety and efficacy were proven in TANGO randomized clinical trial. This multicenter retrospective study included 1032 HIV virologically suppressed patients switching to DTG+3TC from 13 Spanish hospitals. DTG+3TC provided high rates of undetectable viral load over 96%, corresponding to 96.6% (889/921) at 24 weeks, 97.5% (743/763) at 48 weeks, and 98.3% (417/425) at 96 weeks. No significant differences are evident when comparing the total population according to sex, presence of comorbidity, or presence of AIDS. The analysis for paired data showed an increase in CD4+ cell count. A statistically significant increase in CD4+ lymphocyte count was found in those without comorbidities in the three-time series analyzed [average increase at 24 weeks: 48.7 (SD: 215.3) vs. 25.8 (SD: 215.5), p-value = 0.050; a mean increase at 48 weeks: 75.1 (SD: 232.9) vs. 42.3 (SD: 255.6), p-value = 0.003; a mean increase at 96 weeks: 120.1 (SD: 205.0) vs. 63.8 (SD:275.3), p-value = 0.003]. In conclusion, our cohort demonstrates that DTG+3TC is an effective treatment strategy for virologically-suppressed PLWHIV independent of age, sex, and HIV stage, as well as a safe and durable strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Division, Hospital Universitario de Burgos, 09006 Burgos, Spain.
- Infectious Diseases Division, Hospital Universitario Clínico de Valladolid, 47003 Valladolid, Spain.
- Infanta Leonor University Hospital Research and Innovation Foundation, 28031 Madrid, Spain.
- Infectious Diseases Department, Hospital Universitario de Donostia, 20014 San Sebastián, Spain.
- Infectious Diseases Division, Hospital Universitario de La Princesa, 28006 Madrid, Spain.
- Infectious Diseases Division, Hospital Universitario Puerta de Hierro, 28222 Madrid, Spain.
ORCID-Profile: Carlos Dueñas, Roberto Pedrero, Guillermo Pousada, Estela Moreno, María-Antonia Sepulveda, Jesús Troya
Zitieren
APA
Buzón, L., Dueñas, C., Pedrero, R., Iribarren, J. A., de Los Santos, I., Díaz de Santiago, A., Morán, M. Á., Pousada, G., Moreno, E., Ferreira, E., Iglesias, A., Martín, C., Gómez, J., Rodríguez, L., Egido, M., Sepulveda, M. A., & Troya, J. (2023). Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic. Viruses, 15(2), 322. https://doi.org/10.3390/v15020322
Vancouver
Buzón L, Dueñas C, Pedrero R, Iribarren JA, de Los Santos I, Díaz de Santiago A, et al. Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic. Viruses. 2023;15(2):322. doi:10.3390/v15020322
BibTeX
@article{Buzn2023,
author = {Buzón, Luis and Dueñas, Carlos and Pedrero, Roberto and Iribarren, Jose Antonio and de Los Santos, Ignacio and Díaz de Santiago, Alberto and Morán, Miguel Ángel and Pousada, Guillermo and Moreno, Estela and Ferreira, Eva and Iglesias, Alicia and Martín, Cristina and Gómez, Julia and Rodríguez, Laura and Egido, Miguel and Sepulveda, María-Antonia and Troya, Jesús},
title = {Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic},
journal = {Viruses},
year = {2023},
volume = {15},
number = {2},
pages = {322},
doi = {10.3390/v15020322}
}
EUVIMED